pirfenidone   Click here for help

GtoPdb Ligand ID: 7532

Synonyms: AMR-69 | Esbriet®
Approved drug Immunopharmacology Ligand
pirfenidone is an approved drug (EMA (2011), FDA (2014))
Compound class: Synthetic organic
Comment: Pirfenidone is an anti-fibrotic drug. In addition to its proven anti-fibrotic effects in lung tissue, pirfenidone-induced in vitro and in vivo anti-fibrotic activity has been reported in experimental liver and renal fibrosis [3,5].

SARS-CoV-2: COVID-19 is accompanied by inflammation and fibrotic lung damage that appears to persist beyond immediate recovery. The clinical potential for applying the antifibrotic activity of pirfenidone to help treat COVID-19-related pulmonary fibrosis is reviewed by Ferrara et al. (2020) [2].
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 1
Hydrogen bond donors 0
Rotatable bonds 1
Topological polar surface area 21.48
Molecular weight 185.08
XLogP 3.08
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES Cc1ccc(=O)n(c1)c1ccccc1
Isomeric SMILES Cc1ccc(=O)n(c1)c1ccccc1
InChI InChI=1S/C12H11NO/c1-10-7-8-12(14)13(9-10)11-5-3-2-4-6-11/h2-9H,1H3
InChI Key ISWRGOKTTBVCFA-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
Approved to treat idiopathic pulmonary fibrosis (IPF) [4].
Mechanism Of Action and Pharmacodynamic Effects Click here for help
The precise molecular mechanism of action of this drug is not fully resolved, but may involve a reduction in the production of fibroblasts and pro-fibrogenic substances in the lungs of IPF patients [1], thus slowing disease progression.
External links Click here for help